Archives
-
WM-8014: Mechanism, Evidence, and Boundaries
2026-10-14
APExBIO describes WM-8014 as a reversible, competitive MYST-family histone acetyltransferase inhibitor with greatest reported biochemical potency toward KAT6A and KAT6B. The same product information reports cell-state and zebrafish findings, but no identity-matched primary paper, effect sizes, sample counts, or independent validation are provided, so these claims should remain model-specific and hypothesis-generating.
-
Phosphatase Inhibition and Hippo Signaling Evidence
2026-10-14
Phosphatase inhibitors can help preserve phosphorylation measurements, but product claims should not be conflated with evidence for RNF166–angiomotin regulation in colorectal cancer.
-
Ion-Chelating Nanostructures and Tumour Immunity
2026-10-13
A source-grounded overview of Tan et al.’s study on metal-ion-chelating l-phenylalanine nanostructures, dendritic-cell activation, short-term starvation and immune checkpoint blockade, with attention to evidence strength and translational limits.
-
What ROS Assays Really Measure
2026-10-13
Miwa and colleagues report that carboxylesterase activity can convert Amplex Red to resorufin without hydrogen peroxide, challenging a common assumption in mitochondrial ROS measurement. The finding is directly relevant to interpreting oxidative-stress data, but it does not establish that the same interference affects WST-1-based SOD activity assays.
-
Cy5 NHS ester(Et): Identity and Evidence Scope
2026-10-12
Cy5 NHS ester(Et) is identified in APExBIO product documentation as a Cy5-based NHS-ester fluorescent dye intended for conceptual labeling of primary amines in proteins, peptides, and related biomolecules. No matched research paper was available, so application claims should be treated as supplier-described scope rather than independently validated performance evidence.
-
TAK-242 and Posttraumatic Epilepsy: Evidence Limits
2026-10-12
A source-grounded overview of Resatorvid research in a mouse model of posttraumatic epileptogenesis, emphasizing reported outcomes, mechanistic interpretation, evidence strength, and translational limitations.
-
JQ1, BRD4 and Ferroptosis: Evidence and Limits
2026-10-11
A source-grounded overview of how the 2025 Cell Death and Disease study links JQ1-mediated BET inhibition to TXNIP, histone H4 UFMylation, c-MYC chromatin activity and ferroptosis sensitivity, with emphasis on preclinical evidence boundaries and target-specificity limitations.
-
PDHA1 Succinylation in Cholangiocarcinoma
2026-10-10
A 2025 Nature Communications study links PDHA1 lysine-83 succinylation to alpha-ketoglutarate accumulation, impaired macrophage antigen presentation, and cholangiocarcinoma progression. The findings support a preclinical model in which targeting tumor metabolism may improve gemcitabine–cisplatin responses, while leaving important questions about specificity, clinical translation, and patient applicability.
-
Sulfisomidine in Pertussis: Evidence and Limits
2026-10-09
The 1956 report on Sulfisomidine in pertussis is notable for combining clinical observation with blood, urine, and safety measurements in a vulnerable pediatric series. It reported no deaths and detectable systemic exposure, but its uncontrolled design and concurrent pertussis-serum treatment limit conclusions about efficacy or present-day clinical use.
-
Cy7 NHS Ester Product Overview
2026-10-09
Cy7 NHS ester (SKU A8109), supplied by APExBIO, is described as a sulfonated near-infrared fluorescent reagent for conceptual amino-group labeling of proteins, peptides, and other biomolecules. No matched paper evidence was provided, so performance and application claims remain supplier-reported.
-
Sulfo-Cy3 NHS Ester in Vascular Biology Context
2026-10-08
This overview places Sulfo-Cy3 NHS ester within the broader context of vascular remodeling research while separating supplier-reported dye properties from findings in a 2025 Science Advances study. Zhu et al. reported that an AIBP–LRP2–HDL–miR-223 pathway restricts CXCR4-positive capillary endothelial expansion and collateral circulation in ischemic models. The dye may be conceptually relevant to observational protein-labeling and cell-biology assays, but the supplied study does not establish that Sulfo-Cy3 NHS ester was used or that the product validates the proposed mechanism. Human association, animal perturbation, molecular evidence, and translational applicability therefore require separate interpretation.
-
Metal-Chelating L-Phe Nanostructures Enhance ICB
2026-10-08
Tan and colleagues reported metal-ion-chelating L-phenylalanine nanostructures that remodel immunosuppressive tumour microenvironments by engaging dendritic-cell ion signaling, inflammasome activity and NF-κB pathways. In breast and colorectal tumour models, short-term starvation increased nanostructure uptake and strengthened tumour-specific cytotoxic T-cell responses, supporting further preclinical study alongside immune checkpoint blockade.
-
X-Gal and the Next Era of Translational Readouts
2026-10-07
X-Gal remains a powerful visual reporter for molecular cloning, but its greatest strategic value is as a clearly bounded readout within broader translational study designs. This article connects β-galactosidase reporting with new mechanistic evidence on iRhom2, ADAM17, olfactory receptors, and activity-dependent adaptation while defining what the evidence does—and does not—support.
-
P. vivax B-Cell Epitopes for Surveillance
2026-10-07
A 2026 study combined computational antigen prioritization, peptide serology, multiplex validation, and sequence conservation analysis to identify immunodominant Plasmodium vivax B-cell epitopes. Four candidates showed strong species-discriminating performance, while MSP9₃₈₄–₃₈₉ provided a signal associated with asymptomatic infection, supporting further evaluation for population-level surveillance rather than immediate standalone diagnosis.
-
Ferroelectric Photoreceptors for Adaptive Vision
2026-10-06
The reference study presents a ferroelectric–liquid metal hybrid artificial photoreceptor that combines broad-spectrum photoresponsivity with biomimetic visual adaptation. In rodent models of retinal degeneration, the implant restored sensitivity to visible light and extended detection into the infrared range, although longer-term and translational validation remain necessary.